8 hours
The Stanford Faculty Club
Starting at USD 162
Thu, 17 Jul, 2025 at 09:00 am to 05:00 pm (GMT-07:00)
The Stanford Faculty Club
439 Lagunita Drive, Stanford, United States
Welcome to the Cancer Therapy Tech Conference! Join us at The Stanford Faculty Club for a day filled with cutting-edge advancements in cancer treatment technology. Our event will feature keynote speakers, interactive workshops, and networking opportunities with industry experts. Whether you're a researcher, clinician, or tech enthusiast, this conference is the perfect place to stay updated on the latest breakthroughs in cancer therapy. Don't miss out on this exciting opportunity to be a part of the future of cancer treatment!
Info: Transforming Cancer Care: How AI, Systems Biology, and Vionix Biosciences are Advancing Predictive, Preventive, and Personalized Medicine. Vivek Wadhwa is a tech entrepreneur, academic, and author known for his research on exponential technologies. He is a Distinguished Fellow at Carnegie Mellon University's College of Engineering, and has held positions at Duke, Harvard, Stanford, and Singularity University. He's also a syndicated columnist for The Washington Post and has authored several books. Wadhwa's work focuses on the impact of technologies like robotics, AI, and synthetic biology, and their potential to solve global challenges.
Info: Julieta Gabiola, MD, Clinical Professor of Medicine at Stanford and School of Medicine Faculty Senate, mentors students and residents in clinical practice and global health. She leads ABC’s for Global Health, providing healthcare access to underserved communities in the Philippines and exposing students to public health. She co-authored Patient-Focused Clinical Assessment: The Art and Science of Clinical Data Gathering (Pearson) and contributed to DISRUPT, a book on Filipina women driving change. She also produces the podcast Medicine for Good, putting a human face to medicine. Dr. Gabiola has received numerous honors, including the Top 100 Most Influential Filipina Women in the World, as well as teaching and humanitarian & Outstanding Contribution to Promoting Health Equity awards at Stanford.
Info: Ari Akerstein - Co-Founder, CEO of CancerHacker Lab/ Brad Power - Co-Founder, CEO of Cancer Patient Lab/ Chris Apfel - President, CEO of SageMedic Corp.
Info: Eric Heinz - Founder, CEO, and general partner of Heinz Ventures / Lu Zhang - Founder & Managing Partner at Fusion Fund / Malika Dale - Advisor at Lexi Ventures/Associate at DigitalDx Ventures
Info: Charles Keller - Scientific Director at Children's Cancer Therapy Development/ Cristabelle De Souza - Instructor, Radiation on Oncology - Radiation and Cancer Biology / Julianne Averill - Managing Director at Danforth Advisors /Malika Dale - Advisor at Lexi Ventures & Associate at DigitalDx Ventures
Info: Felix Oen - Mentor at Stanford CARE, Co-Founder CEO of NeoTILa / Laura Hsieh - CEO & Founder of TippingPoint Biosciences / Aimee DeGolyer - Founder & CEO of REPROSENT / Marty Tenenbaum - Founder & CEO of Cancer Commons
Info: Ronjon Nag - Founder of R42 Group, inventor, and Adjunct Prof. in Genetics, Stanford Medicine
Info: Brad Niles, Ph.D. serves as the CEO for ARIZ Precision Medicine, after previous roles as COO and VP of Research and Development at ARIZ. He received his Ph.D. from UC Davis, with a Designated Emphasis in Biotechnology and advanced training in Business Development. He has 15 years of experience in cancer research, and has published more than a dozen scientific papers, and was an invited speaker to numerous scientific conferences. In addition, he has managed product development projects for two different biotech startups and is an inventor on numerous RNA-therapeutic patent applications.
Info: Dr. Charles Keller was a practicing pediatric oncologist who, after witnessing the limited options of his patients, sought out a new opportunity and founded his own research facility. Dr. Keller launched the Children’s Cancer Therapy Development Institute (cc-TDI) and has since spent decades devoted to the research of rare, aggressive and difficult-to-treat pediatric cancers.
Info: Mark is a senior business development leader with over 30 years experience in US and international sales and marketing for professional services firms, including Accenture and PriceWaterhouseCoopers. Top-performing consulting and technology solutions executive in closing major sales and revenue initiatives. Global Alliance Director of a blockchain development agency that launched 25 Initial Coin Offerings (ICO's) that raised over $200 million. He served as a registered lobbyist for the British Government creating foreign direct investment to the UK among other roles..
Info: Marco Lobba obtained a PhD from the University of California Berkeley and was a student in the labs of Nobel Laureate Jennifer Doudna and Matthew Francis, Emeritus Chair of the Berkeley Department of Chemistry. In addition, he holds a bachelor’s degree from Pomona College. With his educational foundation rooted at the intersection of chemistry and molecular biology and gene editing, Dr. Lobba cofounded CatenaBio to address the pressing challenge of delivering targeted protein therapeutics. His expertise in protein conjugation has helped advance innovative treatments, such as CRISPR-based editors and cell-based therapies. Dr. Lobba's academic background and experience at UC Berkeley have shaped his vision for revolutionizing precision medicine and developing therapies that were previously unimaginable.
Info: Scientist, CEO, company builder, and investor with a mission to improve health and sustainability. RNA enthusiast. Focused on helping cancer patients survive through better diagnostics and treatment navigation tools. Serial entrepreneur. Advised several small and medium-sized biotech companies and the Danish Ministry of Foreign Affairs, bringing in +$1B deals to Danish Biotech companies. Advised the European Commission on evidence-based innovation and investment policies. Won numerous prizes and awards and raised $8M+ in grants. Worked at Novo Nordisk in several management positions, inventing, developing and bringing multiple products to market worldwide.
Info: Hayley McLaughlin, co-founder and COO for Intelligyn. I've lived across 3 continents, and I want to do my part to close the gap in womens health. I've had a long career in diagnostic imaging, clinical and working within industry and now I am bringing to market an AI driven decision support tool that can elevate the diagnostic performance of any ultrasound examiner to that of an expert.
Info: Mentor at Stanford CARE, Co-Founder CEO of NeoTILa
Info: With over twenty years of experience in neuroscience research, Izi is adept at using a range of molecular, cellular, and systems-level approaches to solve problems in the biological sciences. She also has deep expertise in theoretical research, devising mathematical models of cellular function in health and disease. Her research into the mechanisms of tumor formation has garnered awards from the Society for Neuro Oncology and The American Federation for Aging Research, as well as international press coverage.Izi has led research teams to develop new small-molecule and biological therapies for brain disease; trained personnel on state-of-the-art laboratory techniques; set up tissue culture facilities and molecular biology facilities; designed, manufactured, and validated viral-vector-based gene therapies; isolated, expanded, and evaluated stem cell therapies; and developed custom animal behavior assessments to evaluate neurological disease progression.
Info: I am the founder and CEO of REPROSENT, a startup that uses patient symptom data and AI for continuous process improvement in treating cancer. Through enabling early detection in progression of disease, predicting adverse events, and creating a feedback loop based on real patient experience, we harness what every patient has at their disposal - their own symptom data - and apply it to care. REPROSENT is backed by Y Combinator, and is the winner of the Astellas Pharma Changing Cancer Care Award.
Info: Mark has over 20 years of executive and entrepreneurial experience in the rare disease space at multiple venture backed companies. He held positions of increasing responsibility in business development (culminating as VP) at Dyax Corp, which was acquired by Shire for its FDA-approved drugs for hereditary angioedema. He has been a founder, CEO, or Executive Chair of Lotus Tissue Repair (a Third Rock Ventures company acquired by Shire), PellePharm and Molecular Skin Therapeutics (both BridgeBio companies), SeylanMed and Chromaderm (both merged into Dermbiont), NFlection Therapeutics, and Phoenicis Therapeutics. Mark is a board member of SNAPkids, a San Francisco Bay Area non-profit organization, and an advisor to the CureGM1 Foundation.
Info: California-licensed physician, clinical researcher with 100+ publications including NEJM, impact investor, board member and advisor to over a dozen of life science startups. MD/PhD from the University of Giessen, Germany, and MBA from Wharton, U Penn.
Info: Lunch will be provided
Info: Ari Akerstein - Co-Founder, CEO CancerHacker Lab / Bob Karr - CEO LinkSV / Brad Power - Co-Founder, CEO Cancer Patient Lab / Lu Zhang - Founder/Managing Partner Fusion Fund / Malika Dale - Associate DigitalDX Ventures / Marty Tenenbaum - Founder & Chairman Cancer Commons / Paul Grewal -General Partner SIC Venture Studio / Soyoung Park - General Partner 1004 Venture Partners
Also check out other Business events in Stanford, Health & Wellness events in Stanford, Conferences in Stanford.
Tickets for 2025 Silicon Valley Cancer Tech Conference can be booked here.
| Ticket type | Ticket price |
|---|---|
| Early Bird | 162 USD |
| General Admission | 269 USD |
We have gathered all the information for you in one convenient spot, but please keep in mind that these are subject to change. We do our best to keep everything updated, but something might be out of sync. For the latest updates, always check the official event details by clicking the "Find Tickets" button.
